uniQure (NASDAQ:QURE) Director Jack Kaye Sells 1,993 Shares

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 1,993 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $53,930.58. Following the transaction, the director owned 25,996 shares of the company’s stock, valued at approximately $703,451.76. This represents a 7.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Jack Kaye also recently made the following trade(s):

• On Wednesday, June 3rd, Jack Kaye sold 2,645 shares of uniQure stock. The stock was sold at an average price of $30.01, for a total value of $79,376.45.

uniQure Price Performance

QURE traded up $0.75 during trading on Friday, reaching $27.57. The stock had a trading volume of 835,627 shares, compared to its average volume of 2,601,234. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a 1-year low of $8.73 and a 1-year high of $71.50. The stock has a 50 day moving average of $22.31 and a two-hundred day moving average of $21.76.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. As a group, equities analysts anticipate that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on QURE. Leerink Partners restated an “outperform” rating and issued a $35.00 target price on shares of uniQure in a research report on Monday, March 2nd. Cantor Fitzgerald restated a “neutral” rating and issued a $9.00 target price (down from $55.00) on shares of uniQure in a research report on Monday, March 2nd. Chardan Capital upped their target price on uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Wells Fargo & Company upgraded uniQure from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $15.00 to $60.00 in a research report on Monday, March 9th. Finally, Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, uniQure has an average rating of “Moderate Buy” and a consensus price target of $42.83.

Hedge Funds Weigh In On uniQure

A number of hedge funds have recently modified their holdings of QURE. Woodline Partners LP grew its holdings in shares of uniQure by 25.0% in the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after acquiring an additional 35,175 shares during the last quarter. Legal & General Group Plc acquired a new position in shares of uniQure in the 2nd quarter worth $497,000. Marshall Wace LLP grew its holdings in shares of uniQure by 276.5% in the 2nd quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock worth $3,108,000 after acquiring an additional 163,749 shares during the last quarter. California State Teachers Retirement System acquired a new position in shares of uniQure in the 2nd quarter worth $540,000. Finally, Ameriprise Financial Inc. grew its holdings in shares of uniQure by 38.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock worth $10,622,000 after acquiring an additional 212,218 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.